The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes

James R. Cerhan, Matthew J. Maurer, Brian K. Link, Andrew L. Feldman, Thomas M. Habermann, David L. Jaye, W. Richard Burack, Timothy J. McDonnell, Francisco Vega, Jennifer R. Chapman, Sergei Syrbu, Kiran R. Vij, Giorgio Inghirami, John P. Leonard, Leon Bernal-Mizrachi, Umar Farooq, Thomas E. Witzig, George J. Weiner, Yucai Wang, Juan P. AlderuccioSusan L. Slager, Melissa C. Larson, Shaun M. Riska, Brianna J. Gysbers, Julianne J. Lunde, Tanner W. Reicks, Amy A. Ayers, Colin B. O'Leary, Kathleen J. Yost, Hongfang Liu, Grzegorz S. Nowakowski, Jia Ruan, Dai Chihara, Jean L. Koff, Carla Casulo, Carrie A. Thompson, Jonathon B. Cohen, Brad S. Kahl, Loretta J. Nastoupil, Izidore S. Lossos, Jonathan W. Friedberg, Peter Martin, Christopher R. Flowers

Research output: Contribution to journalArticlepeer-review

Abstract

To address the current and long-term unmet health needs of the growing population of non-Hodgkin lymphoma (NHL) patients, we established the Lymphoma Epidemiology of Outcomes (LEO) cohort study (NCT02736357; https://leocohort.org/). A total of 7735 newly diagnosed patients aged 18 years and older with NHL were prospectively enrolled from 7/1/2015 to 5/31/2020 at 8 academic centers in the United States. The median age at diagnosis was 62 years (range, 18–99). Participants came from 49 US states and included 538 Black/African-Americans (AA), 822 Hispanics (regardless of race), 3386 women, 716 age <40 years, and 1513 rural residents. At study baseline, we abstracted clinical, pathology, and treatment data; banked serum/plasma (N = 5883, 76.0%) and germline DNA (N = 5465, 70.7%); constructed tissue microarrays for four major NHL subtypes (N = 1189); and collected quality of life (N = 5281, 68.3%) and epidemiologic risk factor (N = 4489, 58.0%) data. Through August 2022, there were 1492 deaths. Compared to population-based SEER data (2015–2019), LEO participants had a similar distribution of gender, AA race, Hispanic ethnicity, and NHL subtype, while LEO was underrepresented for patients who were Asian and aged 80 years and above. Observed overall survival rates for LEO at 1 and 2 years were similar to population-based SEER rates for indolent B-cell (follicular and marginal zone) and T-cell lymphomas, but were 10%–15% higher than SEER rates for aggressive B-cell subtypes (diffuse large B-cell and mantle cell). The LEO cohort is a robust and comprehensive national resource to address the role of clinical, tumor, host genetic, epidemiologic, and other biologic factors in NHL prognosis and survivorship.

Original languageEnglish
Pages (from-to)408-421
Number of pages14
JournalAmerican journal of hematology
Volume99
Issue number3
DOIs
StatePublished - Mar 2024

Fingerprint

Dive into the research topics of 'The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes'. Together they form a unique fingerprint.

Cite this